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Tissue engineering aims to structurally and functionally regenerate damaged tissues, which requires the for-
mation of new blood vessels that supply oxygen and nutrients by the process of angiogenesis. Stem cells are a
promising tool in regenerative medicine due to their combined differentiation and paracrine angiogenic ca-
pacities. The study of their proangiogenic properties and associated potential for tissue regeneration requires
complex in vivo models comprising all steps of the angiogenic process. The highly vascularized extraembryonic
chorioallantoic membrane (CAM) of fertilized chicken eggs offers a simple, easy accessible, and cheap an-
giogenic screening tool compared to other animal models. Although the CAM assay was initially primarily
performed for evaluation of tumor growth and metastasis, stem cell studies using this model are increasing. In
this review, a detailed summary of angiogenic observations of different mesenchymal, cardiac, and endothelial
stem cell types and derivatives in the CAM model is presented. Moreover, we focus on the variation in
experimental setup, including the benefits and limitations of in ovo and ex ovo protocols, diverse biological and
synthetic scaffolds, imaging techniques, and outcome measures of neovascularization. Finally, advantages and
disadvantages of the CAM assay as a model for angiogenesis in tissue engineering in comparison with alter-
native in vivo animal models are described.
Impact Statement
The chorioallantoic membrane (CAM) assay is an easy and cheap screening tool for the angiogenic properties of stem cells
and their associated potential in the tissue engineering field. This review offers an overview of all published angiogenic
studies of stem cells using this model, with emphasis on the variation in used experimental timeline, culture protocol (in ovo
vs. ex ovo), stem cell type (derivatives), scaffolds, and outcome measures of vascularization. The purpose of this overview is
to aid tissue engineering researchers to determine the ideal CAM experimental setup based on their specific study goals.
Keywords: angiogenesis, stem cells, chorioallantoic membrane assay, tissue engineering
Introduction
The tissue engineering field has been a booming andstrong evolving research branch of regenerative medicine
during the last decades. Its ultimate goal is the complete
structural and functional restoration of the native tissue or
organ after injury by an interdisciplinary approach of engi-
neering and life sciences.1 Organ transplantation could be a
potential treatment for patients suffering from organ failure,
but its application is limited by the strong imbalance between
the limited supply and high demand, resulting in long waiting
lists of multiple years.2,3 In addition, although the presence of
diverse adult stem cell types has been widely acknowledged,
the intrinsic regenerative capacity of most tissues is very
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limited.4 Therefore, new therapeutic strategies should be
developed to reduce the huge social and economic impact
associated with this major health care issue.
Autologous or allogeneic transplantation of stem cells is
able to replace injured cells by their differentiation capacity
into diverse cell types. In addition, their paracrine properties
even assume a more important role in regenerative medicine
by boosting endogenous repair.5–7 Besides the formation of
new functional tissue, one of the greatest challenges in tis-
sue engineering is the immediate vascular supply of these
newly formed tissues to deliver oxygen and nutrients,
eliminate waste products, and prevent necrosis.8 Successful
survival of transplanted cells depends on the rapid activation
of angiogenesis, which is the formation of new blood vessels
from preexisting ones. This form of neovascularization is
characterized by degradation of the extracellular matrix
(ECM), proliferation, migration, tube formation of endo-
thelial cells, and maturation and stabilization of new blood
vessels by the attraction and attachment of perivascular
cells.9 The process is strictly regulated by a balance between
proangiogenic and antiangiogenic factors captured in the
ECM and expressed by diverse cell types, including endo-
thelial cells.10–12 Several types of stem cells have also been
found to regulate angiogenesis by the production of proan-
giogenic molecules.13–16
The angiogenic capacity of growth factors, cytokines, and
cells is usually studied by in vitro assays, simulating the dis-
tinct steps of the process. The activity of matrix metallopro-
teinases (MMPs) and their tissue inhibitors (TIMPs) can be
tested by zymography as indication for ECMdegradation.17,18
Direct cell counting,19 DNA labeling with bromodeoxyur-
idine (BrdU)20 or propidium iodide (PI),21 and measuring cell
metabolic activity with 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)21 are useful tools for cell
proliferation, while endothelial cell migration is studied by
Boyden transwell22 or scratch experiments.23,24 Finally, ves-
sel network formation capacity is measured in the tube for-
mation assay.25,26 However, the relevance of these in vitro
assays remains questionable, due to the lack of a functional
blood flow, complex ECM, and cells.
Improvement of current angiogenic strategies for tissue
regeneration requires the availability of more sophisticated
in vivo models that could evaluate the impact of test sub-
stances on the angiogenic process in its entirety, including
hind limb ischemia27–29 and matrigel plug animal mod-
els.30,31 These assays are often expensive, time-consuming,
and associated with severe animal suffering. An alternative
regularly used screening tool for angiogenesis is the chick
embryo chorioallantoic membrane (CAM) assay. For this
experiment, test substances are seeded in scaffolds and
placed on the highly vascularized extraembryonic CAM of
fertilized chicken eggs to evaluate their induction of func-
tional blood vessel formation.32,33
This review focuses on the potential of the CAM assay as
model to study the angiogenic capacity of stem cells and
their consecutive use in tissue engineering. An overview of
studies that cover distinct stem cell types, scaffolds, study
protocols, and outcome measurements is given, with par-
ticular attention to the differences between in ovo and ex ovo
approaches. In addition, the benefits and limitations of this
CAM model are discussed and compared with those of al-
ternative in vivo angiogenic models.
Chorioallantoic Membrane During Chicken
Embryo Development
The chicken embryo has extensively been used by devel-
opmental biologists as a reference model to unravel essential
morphological and molecular mechanisms of the general
embryonic development. Because of its easy accessibility and
manipulation, every developmental stage has thoroughly
been documented. The first head-to-tail axis is the primitive
streak that appears from 6 to 7 h of incubation and achieves
its full length after 18–19 h. In the following hours and days,
somites and the primordia of different structures, including
limbs, eyes, ears, heart, and associated vasculature, are
formed. This process is associated with the growing and
bending of the embryo. Feather germs start to develop at
6.5 days, but only become visible after 8 days. During the
second half of the embryonic development, organ systems
further mature, till the chicken hatches on day 20–21.34
Respiration of the chicken embryo depends on the ex-
traembryonic CAM. This highly vascularized membrane
develops by the fusion of the mesodermal layers of the al-
lantois and chorion. The resulting tri-layered CAM consists
of, starting from the eggshell, the chorionic ectoderm, the
fused mesenchyme layer with the major blood vessel net-
work, and the allantoic endoderm (Fig. 1). Two allantoic
arteries and one allantoic vein ensure the interaction with
the embryonic circulation, analog to the umbilical arteries
and veins in mammals.35 CAM development starts on em-
bryonic day 4 as a small vesicle at the height of the head,
after which it enlarges strongly with a threefold increase in
size between day 8 and 12. At this time, the CAM is com-
pletely covering the embryo and a plateau phase is reached,
which is characterized by differentiation and expansion of
the different layers.36
The associated vasculature of the CAM is continuously
remodeled to meet the increasing needs of the chicken
embryo. On day 8, the blood vessel network is restricted to
small arterioles and venules in the mesenchymal layer,
which make contact with capillaries located just beneath the
chorionic ectoderm. These capillaries invade the chorionic
ectoderm and form a complex capillary plexus in close
contact with the eggshell membrane on day 14.36 Respira-
tion is mediated by the transport of venous blood from the
embryo through the allantoic arteries and mesodermal af-
ferents toward the chorion capillaries for gas exchange. The
oxygenated blood flows back through the mesodermal ef-
ferents and allantoic vein to the embryo.37
The first embryonic blood vessels develop by vasculo-
genesis, starting after 42 h of incubation. During this pro-
cess, angioblasts derived from the mesodermal wall of the
yolk sac form a compact plexus, which is further differen-
tiated and luminized to form a network of primitive tubes
with endothelium, red blood cells, and blood plasma. This
vascular system in the yolk sac is functional after 48 h.38,39
Next, new blood vessels are formed by the proliferation of
endothelial cells, causing the lengthening of existing vessels
by the process of sprouting angiogenesis.36,40 Growth fac-
tors, especially fibroblast growth factors (FGFs), in the
chorioallantoic fluid are responsible for this mitogenic ef-
fect.41 After day 10, growth factor concentrations decrease
and endothelial cells stop proliferating, mature, and become
flattened near the eggshell with their nucleus and cytoplasm
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situated on the opposite side to minimize the distance be-
tween oxygen and red blood cells, and to allow optimal
exchange of oxygen and waste products.36,42 During this
stage, neovascularization shifts to the process of intussus-
ceptive angiogenesis, which allows a strong rise in capillary
numbers in just a few hours. This fast blood vessel formation
is needed to meet the steep increasing metabolic needs of the
embryo. In this process, existing capillaries are being split by
the formation of transluminal pillars consisting of collagen
fibril bundles, surrounded by endothelial cell processes.
While the total number of endothelial cells remains stable,
they are thinned out and remodeled to increase the surface of
the vascular network. Several factors, including shear stress
and vascular endothelial growth factor-A (VEGF-A), could
initiate this form of neovascularization.40,43–46 From day 18,
the membrane and its associated blood vessel network de-
generate and the respiratory activity is gradually taken over
by the lungs.37,47,48 In addition to this function, the CAM
plays an essential role in calcium metabolism by transport-
ing calcium from the eggshell to the embryo in an active
way.49 Finally, since the embryonic kidney excretes into the
allantois, the CAM also stores the embryo’s waste products,
such as ammonia, urea, and uric acid.50
CAM as Experimental Model for Angiogenesis
Initially, the highly vascularized CAM has been exploited
by scientists as an in vivo model to investigate tumor bi-
ology and angiogenesis. The very first described study dated
from 1911, which successfully employed the extraembry-
onic membrane to grow implanted chicken sarcoma tu-
mors.51 Two years later, it was demonstrated that the CAM
is also suitable for the transplantation of xenogeneic tissues
without significant impact on their intrinsic morphological
and biological characteristics. Grafting of rat sarcoma was
performed between day 5 and 7 of incubation and allowed to
grow until embryonic day 18, while tumor-induced angio-
genesis was examined.52 Both studies were conducted by
the research group of Rous and Murphy, who stated that the
outer extraembryonic chicken membrane was beneficial to
use because of its location just underneath the shell mem-
brane, its expanded vascular network, and the possibility of
grafting with minimal associated trauma. Moreover, they
suggested the absence of a significant defensive response
against the allogeneic or xenogeneic tissue.51,52
Based on these first results, the CAM assay has been
further adapted and exploited as an experimental model to
study tumor biology,53 angiogenesis,54,55 invasion,56,57
metastasis,58,59 and antitumor therapeutics.60,61 During the
subsequent years, the CAM model was also used for trans-
plantation of other allogeneic and xenogeneic (embryonic)
tissues.62–65 The cultivation of micro-organisms, including
viruses and bacteria, started in 1930s.66–68 Application of
the CAM assay for vascular-related issues was initiated in
the early 1970s. The proangiogenic and antiangiogenic ca-
pacity of diverse molecules, including tumor angiogenesis
factor,69 angiogenin,70 FGF,70 protamine,71 and their asso-
ciated carrier materials,72 have been evaluated using the
FIG. 1. General structure of the CAM of
the chicken embryo. (A) Schematic over-
view of the general anatomy of the fertilized
chicken egg with the embryo and its extra-
embryonic structures. (B) Histological
hematoxylin-eosin staining of a 14-day-old
CAM, showing the trilayered structure con-
sisting of the CE, central mesenchyme layer
(M) rich in BV, and AE. The figures are
original work by our research groups. CAM,
chorioallantoic membrane; CE, chorionic
ectoderm; AE, allantoic endoderm; BV,
blood vessels. Color images are available
online.
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CAM model. In addition, induction of CAM neovascular-
ization by growth factor-secreting cells and their derivatives,
seeded in diverse scaffolds, has also been described and is
further elaborated in this review.
Different Culture Methods of the Chicken Embryo
The vasculature of the CAM can either be investigated
inside the eggshell (in ovo) or the entire egg content can be
grown in a recipient (ex ovo). The latter is also referred to as
the shell-less culture technique or the in vitro method for
chick embryo cultivation73 (Fig. 2). In addition to the cul-
tivation method, CAM protocols also differ in other culture
parameters, including experimental timeline and incubation
settings.
In ovo CAM technique
For the in ovo approach, eggs are rotated during the first
72 h of incubation to prevent attachment of the embryo to
the eggshell. After 3 days, eggs are placed on the side and
able to set under static conditions for short incubation times.
Afterward, 2–3mL albumen is removed and embryos are
kept in their original egg structure in a humidified incubator
with restricted access to the CAM through a small window
that is made in the eggshell with sterile tweezers, drill, or
electric engraving tools. In this way, pressure inside the egg
is changed and sticking of the CAM to the shell membrane
is prevented. Care should be taken to avoid shell dust falling
down on the CAM, which could disrupt its native vascular
development. To prevent dehydration and contamination of
the embryo, holes are sealed with cellophane tape, Parafilm,
or one half of a Petri dish. At a later phase, the window can
be enlarged to facilitate access to the CAM.74–78
Ex ovo CAM technique
In the ex ovo model, the eggshell is gently cracked and
the egg content is transferred to a recipient. The embryo is
then further cultured in an incubator with high humidity and
the developing CAM automatically grows superficially.
Time of explantation is critical for embryonic survival and
is ideally after 60–72 h of incubation. At this early embry-
onic stage, the CAM is not yet attached to the shell. When
explanted after that period, the embryo’s survival rate
drastically decreases since the yolk sac tends to adhere to
the CAM, leading to an increased chance of rupture when
opening the shell.79 In contrast, earlier cracking, as early as
48 h after the start of incubation, has also been described.80
Nevertheless, based on our experience, this also leads to a
lower survival rate (unpublished data).
In addition to the critical timing, embryo transfer is only
successful when there is no damage to any of the embryonic
structures or extraembryonic membranes, which would re-
sult in a decline of the embryo’s viability as well. The yolk
sac membrane is extremely prone to rupture when cracking
is not performed gently. Even with careful cracking, small
microscopic ruptures can occur, which remain unnoticeable
the first days after ex ovo culture and can ultimately lead to
release of yolk and death of the embryo. A frequently used
method is to crack the egg on a sharp object, such as the
edge of a knife, glass, or Petri dish.79,81,82 Nevertheless, the
shock of this action may cause the yolk membrane to break.
FIG. 2. Comparison of the
in ovo and ex ovo embryonic
development of the chicken.
Fertilized chicken eggs were
cultivated in ovo (A) or un-
der shell-less (B) conditions
in a humidified incubator.
For the in ovo culture proto-
col, 2–3mL albumen was
removed after 3 days of in-
cubation (embryonic day E3)
and a window was made in
the shell to visualize the
embryo. Ex ovo cultured
embryos were transferred to
a weigh boat after an incu-
bation period of 62 h. Em-
bryonic development was
followed up every 2 days,
starting from E3, with a
digital camera within in our
research institutes. Color
images are available online.
4 MERCKX ET AL.
D
ow
nl
oa
de
d 
by
 G
en
t U
ni
ve
rs
ity
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
11
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
A second method of cracking the egg is by using a cutoff
wheel (dremel tool) or small jigsaw to make small indents in
the mineral part of the shell, perpendicular to its longitudinal
axis. The egg can then be opened by applying gentle pres-
sure, resulting in a better overall survival.80,83
Finally, the shape and material of recipient also influence
the survival rate of the embryos. Various recipients are
applied, of which round Petri dishes (80–100mm in size)
and square weigh boats of about the same size are the most
commonly used containers.33,73,79,81,83 These recipients are
suitable for studying angiogenesis because of their stability
and limited size, allowing easy manipulation and visuali-
zation by means of stereomicroscopy. In recipients with less
depth (e.g., Petri dishes) the yolk sac is not completely
immersed, which causes increased gravitational pressure on
the yolk sac membrane, more frequent rupturing, and in-
creased embryonic death. While weigh boats are deeper,
allowing the yolk sac to be completely immersed in the
albumen, round Petri dishes are still commonly used, since
they are easily available and usually already sterilized.73 An
alternative recipient that has been described is a sort of
hammock made from cling film that is fixed around the rim
of a glass or plastic cup, used to cradle the embryo in.80,82
However, this type of container is less convenient for
studying the surface of the CAM because of its larger size.
Advantages and disadvantages of both culture models
The risk of contamination is an important issue for both in
ovo and ex ovo culture methods, but is higher for the latter,
because of the associated extra manipulations and larger sur-
face of the egg content that is exposed. Contamination not only
decreases embryo’s survival rate but is also detrimental for a
valid angiogenesis assay, because it can lead to a false positive
angiogenic response. Specific precautions to minimize con-
tamination include standard sterile handling procedures, such
as rubbing the hands with antiseptic products, cleaning all
used materials with 70% ethanol, and wiping the bottom part
of the eggs with either 70% ethanol or povidone-iodine. The
latter is preferred since it works instantaneously on both
bacteria and fungi and is not absorbed through the eggshell,
allowing a more thorough cleansing of the eggshells.84 If
possible, working in a laminar air flow hood minimizes con-
tamination, but is not necessary to obtain good results.
The major disadvantages of the ex ovo CAM assay in
comparison to the in ovo method are caused by the higher
number of manipulations and materials needed. In addition,
more precautions are required to maintain high survival
rates. The in ovo approach is a sealed system, which permits
the study of compounds with a short half-life,74 while the
large exposed surface of the ex ovo CAM may lead to ex-
cessive evaporation. Therefore, a stable and high humidity
must be kept at all times, which can be achieved by working
with individual boxes with holes to allow air circulation and
containing an additional water source. It should be noted
that the absence of the eggshell could cause preterm death,
since older bird embryos rely on partial breakdown of the
eggshell for essential nutrients, such as calcium and phos-
phates.85 Studies that require embryos to survive past day 18
of incubation demand the addition of these nutrients.86
Despite these practical issues, the ex ovo CAM model has
also a number of advantages. First of all, this approach results
in a larger CAM area for experimental procedures compared
to the in ovo method. Therefore, the amount of technical
replicates per embryo can be increased, which minimizes
interembryo variation in experimental settings and number of
animals needed. Second, (real time) visualization of the CAM
is much easier when the embryo has been brought ex ovo and
the relatively easy access to the CAM opens a new range of
otherwise impossible experimental designs.87,88 These ben-
efits of better visualization and manipulation have made the
shell-less culturing technique a popular model.
Comparative studies between both cultivation systems
could not demonstrate significant differences in size and
weight of chicken embryos on embryonic day 10, 13, and
15. Moreover, chondrification, ossification, and nerve
myelination run in parallel between in ovo and ex ovo cul-
tures during the first 15 days of embryonic development.80
These data suggest that isolation of the embryo from its
normal eggshell structure has no significant impact on its
native maturation. Nevertheless, Kirchner et al. showed a
different course of the fractal dimension and vascular den-
sity of the CAM in time for both culture methods.76
Therefore, the choice of cultivation system should be well
considered and depends on the used experimental setup. Both
methods have already been successfully applied to study the
angiogenic potential of stem cells (Table 1).
Other culture variables
Various chicken strains from diverse breeders have been
used, including white22,75,89 and brown90 leghorn eggs.
Although studies comparing the CAM vasculature and an-
giogenesis between breeds are lacking, a significant impact
on study outcome could be expected. For example, variation
in sensitivity for viruses has already been described.91
Furthermore, eggs are cultured in diverse incubators with
various temperature and humidity settings ranging from
37C to 38.5C and 55% to 80%, respectively.75,77,92–94
Application of stem cells or their derivatives on the CAM
has already been described starting from embryonic day 5, but
might also be postponed to day 11. Starting the experiment in
the initial slow-growing phase of the CAM or in its steep
phase between embryonic day 8–12 will have a strong impact
on measured background and stimulated angiogenesis levels.
Most authors prefer this latter phase to induce a stronger an-
giogenic response compared to baseline values. Exposure
time of the CAM to the test substance ranges from 24 h to
10 days (Table 1). The ideal incubation period might depend
on several parameters, including stem cell type, start day of
incubation, egg culture conditions, physical and chemical
properties of the scaffold, and associated release and break-
down rate of angiogenic components. To prevent a decrease
in the angiogenic action of stem cells or their secreted factors,
repeated administration on a regular basis can be per-
formed.75,94 The CAM assay allows the application of mul-
tiple scaffolds per egg, which could reduce the number of
animals needed.95 Nevertheless, mutual interference between
distant scaffolds cannot be excluded.
Testing the Angiogenic Capacity of Stem Cells
and their Derivates in the CAM Assay
The potential of numerous stem cell types to induce
neovascularization in the CAM assay has already been
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thoroughly documented. However, direct comparison be-
tween these studies is compromised by inconsistencies in
type and number of transplanted stem cells, their tested
paracrine secretion fractions, and the experimental setup,
including egg culture conditions, experimental timeline,
used scaffolds, and outcome measures for blood vessel
formation (Table 1). All these parameters might influence
the observed results on neovascularization and the preferred
study protocol depends on the aimed research goals.
Test substance
Stem cells
Mesenchymal stem cells. The most extensively studied
stem cell type in the field of tissue engineering is the
mesenchymal stem cell (MSC), which is also reflected in
the number of studies testing their angiogenic properties in
the CAM. This cell population is characterized by its
plastic adherence, fibroblast morphology, expression of
several markers, including CD73, CD90, and CD105, and
the absence of endothelial and hematopoietic surface
markers such as CD34 and CD45. In addition, they possess
a trilineage differentiation potential toward adipoblasts,
chondroblasts, and osteoblasts.96 MSCs can be isolated
from various tissue sources, including bone marrow,97
adipose tissue,98 placenta,99 Wharton’s Jelly of the um-
bilical cord,100 and soft tissues associated with teeth.101
Proangiogenic properties have already been assigned to
these stem cells in diverse in vitro and in vivo animal
models, including the CAM assay.13–15,22 Table 1 gives a
detailed overview on the tested MSCs and the observed
results in this latter assay.
Several research groups showed that application of bone
marrow-derived MSCs (BM-MSCs) on the CAM induced
neovascularization.89,102–104 Oskowitz et al. demonstrated
that this effect was enhanced after serum deprivation of the
cells during 30 days.89 Similarly, MSCs isolated from adipose
tissue (AT-MSCs), Wharton’s Jelly (WJ-MSCs), placenta
(Pl-MSCs), newborn skin (NSSCs), and soft tissues in and
around the tooth penetrated the chicken embryo and increased
functional blood vessel growth in the CAM15,22,78,92,93,105–111
(Table 1). These effects are mediated by their incorporation
into newly formed blood vessels or paracrine secretion of
proangiogenic factors that stimulate the host chicken endo-
thelial cells. In case of NSSCs, Pl-MSCs, and WJ-MSCs, the
angiogenic response was stronger when the cells were dif-
ferentiated into endothelial cells before their implanta-
tion.90,110,111 In contrast, Kaushik and Das could not detect a
significant impact of WJ-MSCs on the number and length of
blood vessels in the CAM, but the exact amount of trans-
planted cells was not mentioned in this study.90
Finally, Comsa et al. demonstrated a strong mutual in-
teraction between implanted human MSCs (hMSCs) and
chicken MSCs (cMSCs) present in the CAM. Transplanted
hMSCs formed complex clusters in the chorionic epithelium
with the induction of new vessel sprouts deriving from ex-
isting mesodermal vessels. In addition, cMSCs were pro-
moted to organize into cord-like and capillary-like
complexes in the chorionic epithelium and mesoderm. In
parallel, hematopoiesis of cMSCs could be observed within
these structures. Nevertheless, the tissue source of the used
hMSCs was not clear in this study.112
Cardiac stem cells. Although present at very low per-
centages, different resident stem cell types have successfully
been isolated from the adult cardiac tissue. Based on their
expression of Islet-1,113 c-kit,114 and stem cell antigen-1,115
three different types of cardiac stem cells (CSCs) have been
discriminated. In addition, cardiosphere-derived cells116 and
cardiac atrial appendage stem cells (CASCs)16 are defined
by their isolation from self-assembling multicellular clusters
of stem and progenitor cells or cardiac atrial appendages,
respectively. CASCs express a plethora of proangiogenic
factors and promote in vitro endothelial cell proliferation,
migration, and differentiation. Moreover, transplantation of
CASCs on the CAM promoted in ovo blood vessel forma-
tion.16 In addition, hBM-MSCs differentiated toward car-
diopoietic stem cells have been tested in the CAM assay by
Wolint et al. Cell-seeded scaffolds were infiltrated with
perfused blood vessels in a time-dependent way. Culturing
these stem cells in 3D microtissues could improve their in
ovo proangiogenic effect, resulting in higher blood vessel
density and better perfusion efficacy.95
Endothelial progenitor cells. Vasculogenesis is associated
with the formation of new blood vessels by differentiation of
endothelial progenitor cells (EPCs) or angioblasts, in con-
trast to angiogenesis. This neovascularization process is
dominant in the embryonic phase. Circulating EPCs were
first isolated from the peripheral blood by Asahara et al. in
1997.117 These cells are attracted to angiogenic foci in
mouse and rabbit hind limb ischemia and myocardial in-
farction models, resulting in postnatal vasculogenesis.117,118
In addition to their differentiation capacity, EPCs secrete
proangiogenic factors and exert positive paracrine effects on
endothelial cell survival, proliferation, migration, and tube
formation.119–121 In the CAM assay, GFP-labeled EPCs
induced neovascularization and actively incorporated into
the newly formed vasculature.122 Transfection of murine
embryonic EPCs with angiopoietin-1 mRNA improved their
in ovo proangiogenic potential.123 Application of umbilical
cord-derived outgrowth endothelial cells, a specific sub-
population of EPCs, increased the number of functional
CAM blood vessels and associated perfusion.124
Stem cell-derived conditioned medium. As mentioned in
the previously cited studies, most stem cells induce an-
giogenesis mainly in a paracrine way. This hypothesis has
also been confirmed by applying solely conditioned me-
dium (CM), which is cell culture medium incubated with
stem cells for several hours to days and containing all se-
creted factors.
Mesenchymal stem cells. BM-MSC-derived CM from
different animal species successfully enhanced neovascu-
larization.13,77,125,126 When these BM-MSCs were presti-
mulated with a combination of proinflammatory cytokines
interferon-g (IFN-g) and tumor necrosis factor-a for 12 h, a
stronger angiogenic response was induced.125,126 Applica-
tion of canine BM-MSC-derived CM also resulted in higher
blood vessel density in the CAM and was associated with an
increase in the expression of chicken proangiogenic genes,
including MMPs, FGF-1 and angiogenin, and inflammatory
mediators, such as IFN-g.77
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Our comparative study of the angiogenic potential of
human dental pulp stem cells (hDPSCs) and hBM-MSCs
confirmed the in ovo proangiogenic effect of 25X concen-
trated CM of hBM-MSCs. In contrast, concentrated hDPSC
CM did not induce neovascularization in the CAM, despite
the angiogenic capacity of the cells themselves.127 These
data suggest that hDPSC-secreted factors are not sufficient
to induce an in ovo proangiogenic response, possibly caused
by the limited half-life of secreted growth factors.
Similar results were obtained for nonconcentrated hAT-
MSC-derived CM, which only enhanced angiogenesis in the
CAM assay when parental cells were electrically stimulated
for 72 h. This pulsed electrical stimulation upregulated the
secretion of proangiogenic and antiangiogenic proteins
VEGF-A, thrombospondin-1 (TSP-1), TIMP-1, and mono-
cyte chemoattractant protein-1 (MCP-1), while Serpin-E1
was significantly downregulated.75 CM derived from hAT-
MSCs cultured on collagen-glycosaminoglycan (GAG)
matrix had a stronger angiogenic effect compared to me-
dium originating from hAT-MSCs cultured on other scaf-
folds (i.e., chitosan films and fibrin matrices).94
The angiogenic capacity of CM derived from hPl-MSCs
has only been studied in the chick yolk sac membrane assay
and prestimulation of these cells with a combination of
omega-3 polyunsaturated fatty acids increased their in ovo
angiogenic potential.128
Cardiac stem cells. Medium derived from CASCs in-
creased the number of CAM blood vessels growing toward
the scaffold after 3 days, when concentrated 20 times.16
Up to now, other CSC types have not been tested in the
CAM assay.
Stem cell-derived extracellular vesicles. Besides their
secretion of soluble mediators, stem cells release extracellular
vesicles (EVs) in their CM. These nanoscale membrane-bound
particles play an essential role in cell-to-cell communication
by transferring proteins, miRNAs, and DNA between cells.
Based on their size and origin, three different particle types
have been discriminated, namely apoptotic bodies, micro-
vesicles, and exosomes.129,130 MSC EVs from different tissue
sources contain a plethora of proangiogenic and antiangiogenic
mediators. Moreover, they induce in vitro endothelial cell
proliferation, migration, and tube formation and in vivo func-
tional improvements in animal models of diseases character-
ized by disturbed vascularization, such as wound healing,
stroke, and myocardial infarction.131–135 However, our re-
search group did not observe an angiogenic response in the
CAM assay for human MSC EVs derived from the bone
marrow or from the dental pulp.127 In contrast, the exosomal
subpopulation of human umbilical cord-derived MSCs (hUC-
MSCs) increased the number of CAM blood vessels. Akt
overexpression in the parental cells improved the angiogenic
capacity of these exosomes.136
Scaffolds
To apply stem cells or their derivates on the CAM, di-
verse scaffolds have been used (Table 1). Selection of
scaffold should be based on several important criteria in-
cluding biocompatibility, bioactivity, and porosity. In ad-
dition, preservation of the viability and biological functions
of stem cells should be guaranteed. Based on the density of
the scaffold material, the release rate of cells and their
associated secreted factors could vary. Moreover, some
scaffolds might stimulate or inhibit baseline neovascular-
ization themselves in the chicken membrane. The best
choice is also depending on the desired outcome measure,
such as blood vessel infiltration of the scaffold or general
stimulation of neovascularization in the embryonic mem-
brane137–143 (Table 2).
The most frequently used scaffolds consist of ECM ma-
terials that resemble the in vivo natural 3D environment to
preserve stem cell characteristics and functional properties
and improve their survival.Matrigel is a basementmembrane
extract derived from mouse Englebreth-Holm-Swarm (EHS)
sarcoma. This complex mixture of structural proteins
(mainly laminin, collagen IV, and enactin), growth factors,
and associated binding proteins is extensively used in the
CAM assay15,16,22,89,90,102 and other in vitro and in vivo
angiogenic assays because of its rich cell-supporting com-
position.144 Nevertheless, batch-to-batch variation and
presence of intrinsic angiogenic mediators should be taken
into consideration when interpreting the results.145,146 To
limit the intrinsic angiogenic capacity of this scaffold, the
levels of growth factors, such as epidermal growth factor,
insulin-like growth factor-1, and platelet-derived growth
factor, are decreased in a commercially available ‘Growth
factor-reduced Matrigel’.145 Other widely applied carriers
are collagen-based scaffolds, such as Gelfoam sponges of
collagen-degraded gelatin,13 Optimaix-3D biodegradable
sponges of porcine collagen,95 and porous Integra Matrix
consisting of cross-linked bovine tendon collagen and
GAGs.109 In addition, fibrin stem cell-seeded matrices of
polymerized fibrinogen and thrombin or collagen type I have
been tested in the CAM assay.92,147
Membranes made of various synthetic materials have also
regularly been used as support to place stem cells or their
derivates on the chicken membrane. Straw disks,111 filter
paper,94,136 confetti (hydrophilic polytetrafluoroethylene)
membranes,110 biologically inert elastic Optilene (hernia
fibrous polypropylene),106 and nylon meshes107 are possible
successful alternatives for the more complex ECM-based
scaffolds. The bioactive glass-ceramide composite 45S5
Bioglass is mainly studied in the field of bone tissue en-
gineering, because of its positive effect on bone forma-
tion.148 In addition, this 3D scaffold is biocompatible with
no effect on chicken embryonic development, neovascular-
ization, or inflammation.149 Therefore, it is an ideal carrier
to study the angiogenic potential of stem cells in the CAM
model as demonstrated by Handel et al.106
Biological materials are also promising candidates as de-
livery vehicles of stem cells to the CAM. Biocompatible and
biodegradable silk fibroin scaffolds are derived from silk-
worms by chemical processing.150 Kivrak Pfiffner et al. and
Woloszyk et al. applied this hDPSC-seeded carrier system in
the CAM assay, which resulted in the infiltration of perfused
blood vessels in the scaffold.78,108 Chitosan is a natural
substance obtained from chitin present in the exoskeleton of
different animals, including Crustacean. Chitosan-based
scaffolds are biodegradable and biocompatible and their
porosity can be regulated to optimize them for cell seed-
ing.151 Cheng et al. used a chitosan hydrogel to test the in ovo
angiogenic potential of hAT-MSCs.105
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Finally, silicone or plastic rings havebeenplacedon theCAM
to define the location wherein stem cells or their derivates are
administered.75,77,93,112 This method allows the fast distribution
of stem cells and their secreted factors over the embryonic
membrane, which is in contrast with the previously mentioned
viscous scaffolds that permit the gradual release of angiogenic
factors. Some researchers combine these rings with other scaf-
folds to flatten the CAM around the delivery site.78,95,108
Comparative studies using more than one scaffold type
emphasize the impact of the chemical, physical, and biological
properties of these carriers on the angiogenic potential of stem
cells or their derivates. While cell-free 45S5 Bioglass and
hernia meshes had no intrinsic effect on CAM neovascular-
ization, hAT-MSCs in hernia scaffolds induced a stronger
blood vessel infiltration compared to stem cells seeded on the
bioactive glass, probably caused by their higher proliferation
rate and VEGF secretion.106 In addition, a supporting hydrogel
consisting of both gelatin and chitosan was needed for hAT-
MSCs to increase the number and branching of CAM blood
vessels, since cell-seeded chitosan scaffolds had no effect.105
Gelatin supplementation mimics the in vivo ECM and im-
proved stem cell adhesion and proliferation.152
Wahl et al. compared the effect of three different scaf-
folds (i.e., chitosan films, fibrin matrices, and collagen-GAG
matrices) on the distribution, attachment, survival, and
protein secretion profile of hAT-MSCs. Cell attachment was
significantly lower in chitosan films compared to other
scaffolds with the accumulation of stem cells at the seeding
side. In the fibrin matrices, cells were mainly concentrated
in the core, while a gradient from the seeding surface to the
opposite side was observed for the collagen-GAG matrices
in which cell viability was the highest. Moreover, variation
in secretion of angiogenic proteins, such as VEGF,
interleukin-8 (IL-8), and placental growth factor, was de-
tected between the scaffolds. This resulted in significant
differences in the proangiogenic potential of their CM in the
CAM assay. CM from hAT-MSCs cultured on collagen-
GAG matrices had the strongest effect on ex ovo blood
vessel formation, followed by fibrin and chitosan matrices.94
Outcome measures of neovascularization
To describe the angiogenic response induced by stem
cells in the CAM assay, diverse outcome measures have
Table 2. Overview of Scaffolds Used to Deliver Stem Cells and Their Derivatives
on the Chorioallantoic Membrane
General characteristics Scaffold examples Stem cells References
Natural materials
Natural ECM proteins, resembling the in vivo
native 3D environment
Support stem cell characteristics, survival,
proliferation, adhesion, and biological
functions
Biocompatible, biodegradable, bioactive
Less controllable morphology, physical
and chemical properties
Poor mechanical strength
High lot-to-lot variability
Less scalability
Strong purification needed to prevent
contamination and immune reactivity
Costly
Fast degradation
GF-reduced Matrigel BM-MSCs, WJ-MSCs,
DPSCs, SCAPs, CASCs
15,16,22,89,90,102,127
Gelfoam (gelatin) sponges BM-MSCs, AT-MSCs 13,105
Optimaix-3D sponges Cardiopoietic stem cells 95
Integra matrices WJ-MSCs 109
Fibrin matrices AT-MSCs 92
Silk fibroin scaffolds DPSCs 78,108
Chitosan hydrogels AT-MSCs 105
Alginate hydrogels EPCs 124
Synthetic materials
Controllable, reproducible, high-scale
production
High manipulation of degradation rate,
morphology, mechanical, physical,
and chemical properties
Less biocompatible
Biologically inert
Potential host immunological response
Modifications needed to enable cell
supporting/adhesion
Straw disks Pl-MSCs 111
Filter paper AT-MSCs, UC-MSCs 94,136
Confetti membranes NSSCs 110
Optilene (hernia) meshes AT-MSCs 106
Nylon meshes AT-MSCs 107
Ceramics
Bioactive, biocompatible
Low immune reactivity
High mechanical strength
High porosity
Less degradability
45S5 Bioglass scaffolds AT-MSCs 106
AT-MSC, adipose tissue-derived mesenchymal stem cell; BM-MSC, bone marrow-derived mesenchymal stem cell; CASC, cardiac atrial
appendage stem cell; DPSC, dental pulp stem cell; ECM, extracellular matrix; EPC, endothelial progenitor cell; GF, growth factor; NSSC,
neonatal foreskin stem cell; Pl-MSC, placenta-derived mesenchymal stem cell; SCAP, stem cell of the apical papilla; UC-MSC, umbilical
cord-derived mesenchymal stem cell; WJ-MSC, Wharton’s Jelly-derived mesenchymal stem cell.
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been applied, including methods to quantify the blood vessel
network, (immune)histology, RNA and protein analysis, and
advanced imaging techniques (Table 1).
Methods to quantify blood vessels and their proper-
ties. The most commonly used method is to evaluate the
morphology, distribution, and amount of blood vessels near
the applied treatment onmicroscopic images (Fig. 3A). Based
on these parameters, an arbitrary angiogenic score is given
per egg.89,94 Blood vessel density is also expressed as area
percentage or absolute number of blood vessels that invade
the cell-seeded construct,90 which are present in a selected
test area,77,93,105,106,109–111,125,126,128,136 or that cross a con-
centric circle around the test substance.15,16,22 Some studies
discriminate the blood vessels based on their diameter125,126
or determine the total length or shape of the CAM vascula-
ture.90,95 Although these analyses are standardly performed
double blinded, this analysis method is not completely ac-
curate and observations are not always reproducible. A pos-
sible solution is automatic analysis programs, such as
WimCAM software that allows themeasurement of total vessel
density, vessel network length, and branching points.75 Kirch-
ner et al. successfully applied fractal analysis for the objective
measurement of angiogenesis during CAM development.76
This automation requires high-quality pictures of the vascula-
ture with low background noise, which could be achieved by
cutting out the CAM,15,16,22 adding cosmetic white cream or
zinc oxide suspension underneath the membrane,75,93,109 in-
jecting colloidal gold particles into the vasculature,40 or digi-
tally adjusting the contrast by ImageJ software.77
However, the biggest challenge to measure neovascular-
ization is to discriminate between existing and new blood
vessels. Therefore, some researchers prefer to take pictures
before and after the treatment, but this is not always possible
in each experimental setup.77,128 An alternative solution,
proposed by Nguyen et al., is the application of a double
nylon mesh-seeded scaffold. This standardized technique
allows easy identification of new invaded blood vessels by
focusing on the top mesh, while preexisting CAM vessels
are limited to the bottom mesh (Fig. 3B, C).33
Histological and immunohistological analysis. Histological
analyses and immunostaining provide in-depth evaluation of
the angiogenic reaction of the CAM vasculature. Hematoxylin
and eosin staining is a valuable method to study the general
morphology of the connective tissue and associated blood
vessels.13,110,112 This technique has been used to evaluate
the angiogenic effect of MSC-containing constructs78,92,108
and collagen matrices loaded with human cardiopoietic stem
cells.95 Immunohistochemical and immunofluorescent stain-
ing for endothelial and pericyte markers, such as CD31, von
Willebrandt factor, and a-smooth muscle actin (a-SMA), are
useful tools to analyze the CAM vasculature.108,112 Further-
more, immune-based staining against human antigens is ap-
plied to determine the viability and potential incorporation and
differentiation of the stem cells into newly formed blood
vessels.92,110–112 Another regularly used method to track
transplanted stem cells in the CAM is their prelabeling with
fluorescent dyes such as CellTracker Green104,107,111 or
Fluoresbrite carboxylate microspheres.103
Advanced imaging techniques. In contrast to the afore-
mentioned end-point analyses on tissue sections, other more
advanced imaging techniques allow in vivo visualization of
CAM vasculature. Injection of a radio-opaque contrast agent
into the blood vessels and consecutive measurement of the
X-ray signals by angiography offer a high-resolution real-
time image of the heart and vascular network with low
background noise. Assessed parameters are vessel density,
diameter, and length in time.153 Magnetic resonance imag-
ing (MRI) can be performed on sedated chicken embryos
with paramagnetic contrast agents such as Gadolinium-
DOTA (Gd-DOTA) to measure perfusion capacity at dif-
ferent layers in the cell-seeded scaffolds.78,95,108
Kurz et al. made high-resolution 3D images of the CAM
vasculature with a dual staining for a-SMA and YoPro-1 by
FIG. 3. Different methods to evaluate induced neovascularization in the CAM assay. (A) Application of a proangiogenic
substance induces a typical spoke-wheel pattern of CAM blood vessels growing toward the scaffold. (B, C) Focusing on the
top mesh of a double nylon mesh scaffold enables the evaluation of newly formed blood vessels, which can be distinguished
from the preexisting vessels in the bottom mesh. Micrograph taken in the DAPI channel (excitation 385 nm and emission
463 nm), which shows the dark blood vessels (indicated by arrows) that are growing over the highly autofluorescent mesh.
(D) The CAM vasculature can easily be visualized in 12-day-old chicken embryos by two-photon microscopy without
additional fluorescent staining due to the autofluorescence of the blood vessel network (elastin). In addition, associated
perivascular cells can be seen due to additional DAPI staining of their nuclei. The image shows the green blood vessels
(excitation 800 nm and emission 500–560 nm) and the DAPI-stained nuclei. All data were collected within our research
groups. Color images are available online.
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confocal imaging. Arteries and veins were distinguished,
since veins are devoid of erythrocytes during the fixation
process.154 Miller et al. demonstrated that confocal micro-
scopic analysis of blood vessels injected with FITC-dextran
was more objective and sensitive compared to standard
evaluation of vascular density based on light microscopic
pictures.155 Confocal microscopy uses high-intensity exci-
tation lasers with photons of low wavelength, which could
damage chicken embryo development and limit its use in
long-time follow-up CAM experiments.
A better alternative could be two-photon microscopy,
which is based on excitation by two photons of half the
energy (double the wavelength) compared to confocal mi-
croscopy. The longer wavelength of the photons induces less
tissue injury. At the same time, two-photon microscopy al-
lows deeper tissue penetration, since tissue scattering of
high-wavelength photons is much lower, which could be
very useful for studying the CAM. The 3D capabilities of
two-photon and confocal microscopy are similar, although
in two-photon microscopy, the resolution at higher depth is
maintained, while in confocal microscopy, resolution rap-
idly worsens.156 Therefore, our research group visualized
the CAM vasculature without additional fluorescent staining
(based on autofluorescence) by this microscopic technique
(Fig. 3D). While our data were obtained on fixed CAM
tissues, they do demonstrate that two-photon microscopy is a
promising tool to monitor real-time neovascularization
without additional manipulation due to the autofluorescence
of the blood vessel network. Moreover, in such in ovo sys-
tems, the injection of fluorescent markers against blood vessel
components, such as endothelial cells and pericytes, could
allow more complex analyses. Such intravital imaging of
blood vessels using two-photon microscopy has been used
before in the mouse carotid region,157 skin,158 and brain.159
Analysis of RNA and protein expression. In addition to
direct visualization of the CAM vasculature, angiogenesis
can be studied by measuring the expression of proangio-
genic and antiangiogenic factors in the CAM tissue. Hu-
menik et al. extracted total RNA from CAMs incubated with
CM from canine BM-MSCs. A polymerase chain reaction
(PCR) array for 89 different angiogenesis-related genes was
performed to compare their expression between treated and
nontreated CAMs.77 Protein levels can be measured by
CAM-layered expression scanning. For this assay, proteins
present in CAM tissue samples are transferred onto capture
membrane stacks. By incubation of these membranes with
fluorescently labeled antibodies against the proteins of in-
terest, relative expression levels are determined based on the
fluorescence intensity signals.155
Other Applications of the CAM Assay
Besides the study of the angiogenic capacity of stem cells
and derivates, the CAM assay is frequently used to inves-
tigate tumor growth, morphology, vascularization, and mo-
lecular mechanisms.160–166 Moreover, in vivo invasion of
the epithelial basement membrane and successive metastasis
by tumor cells can be simulated, in contrast to other animal
models where this first barrier is bypassed by directly in-
jecting cells into connective tissue.161,167,168 In addition,
tumor formation is established within a few days due to the
nutrient-rich embryonic membrane and can easily be mon-
itored in real time.160,169 In this way, the CAM model en-
ables to test the efficacy and side effects of potential
anticancer therapeutics in a patient-personalized way, called
‘‘Patient-derived chicken egg model’’ (PDcE model). Tu-
mors grafted onto the chicken membrane closely resemble
the original patient tumor with a high transplantation suc-
cess rate and can rapidly be screened for diverse therapeutic
options.169
In addition to tumor grafts, other allogeneic and xenoge-
neic tissue fractions, including skin, liver, bone, and adrenal
gland fragments, have successfully been transplanted onto the
CAM to induce their growth, remodeling, and vasculariza-
tion.64,170–172 These effects arise from the mutual interaction
between tissue graft and chicken components.170 Tissue re-
perfusion is accomplished by the formation of peripheral
anastomoses between graft and host vasculature and the in-
growth of CAM blood vessels.171,173 The resulting tissue
construct expresses strong similarities with its original mor-
phology and offers opportunities to study physiological pro-
cesses in tissue regeneration and remodeling ex vivo.64,170,172
Testing the suitability of diverse biomaterials for tissue
engineering purposes is another potential application of the
CAM assay. Several parameters, including cell infiltration,
incorporation, angiogenesis, and inflammation, induced by
biological and synthetic scaffolds that differ in chemical and
physical properties, have been monitored in time.142,143,174–176
The responses in the CAM are similar to those observed in
mammalian animal models, which confirms the strong ad-
ded value of this low-cost model for biomaterial screen-
ing.175 In general, rough materials, such as collagen/elastin
and filter membranes, result in neovascularization and in-
flammation, while smooth polymers inhibit angiogenesis.142
The induced chicken embryonal inflammatory reaction is
consistent to that of mammalians with an initial acute in-
flammation that progressively evolves into a chronic reac-
tion associated with fibrosis.174
In addition to biomaterials, new potential drugs and
chemicals are screened for their toxicity and biodistribution
in the CAM model.177 The most regularly used toxicity test
is the Hen’s egg test-CAM assay (HET-CAM). In general,
the CAM is exposed to the test substance for 20 s and the
vascular response is visually evaluated for 5min. Based on
different parameters, including hemorrhage, lysis, and co-
agulation, an irritation score is assigned ranging from non-
irritant to severe irritation. This test is performed to predict
conjunctiva irritation, since the highly vascularized mucous
CAM resembles the eye membranous structure.178 More-
over, toxicity studies on diverse substances, including pes-
ticides, antimicrobiotics, and vehicles, demonstrated similar
results in the HET-CAM and conventional Draize rabbit eye
test.179,180 Although other researchers questioned this cor-
relation,181 these data suggest that the HET-CAM test could
serve as a fast and painless prescreening tool to reduce an-
imal number and suffering. Besides ocular toxicity,182–184
this model is also suitable to evaluate phototoxicity,185,186
carcinogenicity,187 skin toxicity,188–190 and detrimental ef-
fects on tissue growth and development.191
Associated biodistribution of test substances is investi-
gated by intravenous injection in the CAM vasculature.
Tropism and accumulation of new potential anticancer
therapeutics and diagnostic markers, such as photosensitizers
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and drug-loaded nanocarriers, in tumor grafts can be con-
firmed in the CAM model.192–194 In addition, new therapeutic
targets that are accessible through the bloodstream might be
identified.195 Studying the cellular and organ engraftment of
viral infections or cancer cells is another application of the
CAM assay by histology, immunostaining, and real-time
PCR of chicken embryonic tissues.196,197 Moreover, biodis-
tribution can also be analyzed in a noninvasive way using
in ovoMRI after labeling of the test compounds with contrast
agents.198
Benefits and Limitations of the Model
The CAM model is associated with numerous advantages
in comparison with other in vivo models employed within
the angiogenesis and vascular biology research field. One of
the major gains is the cost-effectiveness of the model,199
since the price of a fertilized egg and the associated care is
significantly lower compared to a mouse or rat. Accord-
ingly, the lower costs of the system and the rapid vascular
growth of the CAM provide the opportunity for large sample
sizes and rapid large-scale screening.74,199,200 Moreover,
multiple test compounds might be simultaneously im-
plemented within one CAM as reported, for example, by
Wolint et al.95 The model also provides benefits in terms of
technical simplicity, easy accessibility, and reproducibili-
ty.200,201 Interestingly, the CAM is characterized by a
slowly developing immune system up to day 15 post-
fertilization. Therefore, the study of regenerative processes
induced by transplantation of xenogeneic cells, tissues, or
(bio)materials is of particular interest, since immunological
rejection might be restricted.74,199,201,202
Furthermore, the possibility for real-time in vivo moni-
toring puts the CAM assay to advantage. In particular, as
previously mentioned, ex ovo shell-less CAM culture is
much more accessible for live imaging. Several reports
showed the usage of a wide range of imaging techniques
reaching from conventional microscopy to photoacoustic
microscopy and bioluminescence imaging.203–206 Moreover,
positron-emission tomography (PET), MRI, and computed
tomography (CT) have been demonstrated to be useful tools for
visualization of the CAM.198,206–208 Nonetheless, X-ray-based
procedures, such as PET and CT, might impact the CAM vas-
culature and interfere with observed angiogenic effects.209,210
The choice for this model could also be affected by other
practical matters, including easy availability of equipment
and skilled personnel and limited ethical considerations.
Since the CAM is noninnervated, experiments are not as-
sociated with pain perception by the chicken embryo, which
exempts this model from ethical approval for animal ex-
perimentation.201 Besides these ethical advantages, the
CAM assay also offers other benefits compared to mam-
malian experimentation, such as easy housing accommo-
dations. Moreover, animals do not have to be restrained.200
Nevertheless, there are also several limitations associated
with the CAM model. Although several outcome measures
have been described to quantify angiogenesis, discriminat-
ing newly formed capillaries from preexisting ones is still
challenging, since the CAM possesses a well-built expanded,
actively growing baseline vascular network. Therefore, the
angiogenic response induced by the test stimulus might be
overestimated in this embryonic model, in comparison to the
more physiologically relevant situation in which the vascu-
lature is fully grown and quiescent.74,199 In addition, the
system only allows a short posttreatment observational period
as physiological and morphological changes occur rapid-
ly.74,200 Moreover, the advantageous immune-deficient
properties are limited to embryonic day 15 and a nonspecific
inflammatory response may occur thereafter.201 Moreno-
Jimenez et al. explored a possible alternative approach to
prolong the incubation period on the CAM. Their so-called
double CAM system consists of harvesting the graft tissue
and reimplanting it onto a second CAM.206
Even though the possibility for large sample sizes is ad-
vantageous, it is crucial to decrease interegg variability,
which makes this technique labor-intensive. In addition, one
of the major challenges of the CAM assay is the usage of
measurable outcome methods and the lack of standardization
in protocol, which has previously been illustrated (Table 1).
Importantly, since the CAM model is a non-mammalian
system, alternative drug metabolism might be present com-
pared to other in vivo models.74 Therefore, caution must be
exercised when interpreting results. An additional downside
of the CAM system is the high sensitivity to environmental
factors, such as contamination, changes in pH or oxygen
tension, and other irritants. These factors could impede
growth of the embryo and might be accountable for an
eventual false positive angiogenic response as mentioned
above.74,199,211 Finally, commercially available products,
such as antibodies, cytokines, primers, and microarrays, for
avian species are not widely available.199
Conclusion
Rapid and adequate angiogenesis is a crucial process
within the field of tissue engineering, particularly when this
involves transplantation of scaffolds with (stem) cells.
Without the supply of the essential oxygen and nutrients, the
engrafted cells do not survive. Therefore, numerous research
efforts are focused on enhancing this type of blood vessel
formation and need reliable in vivo models to investigate the
potential of new scaffolds and (stem) cells. Traditional ro-
dent angiogenesis models, such as the mouse matrigel and
hind limb ischemia assays, are time-consuming, costly, and
accompanied with ethical issues. Despite the fact that the
CAM assay is used since more than a century, this type of
experiment is still an excellent tool to study blood vessel
formation as it is simple and inexpensive. While not mam-
malian, transplantation of cells derived from other species is
possible since the chicken embryo is immune incompetent
during the first 15 days of development. It also provides an
answer in personalized medicine as it is feasible to graft
patient-derived tumors on the CAM. In addition, a wide
variety of scaffolds ranging from silicon, collagen, silk, and
chitosan to bioactive glass have already been successfully
applied on the CAM, proving its versatility. As most CAM
assays allow a readout after several days, it may also speed-
up the preclinical research process. Depending on the re-
search question, it is important to consider the in ovo or
ex ovo approach of this assay as described in this review.
Most important disadvantages include the possibility of only
short incubation times, interegg variability, and the non-
mammalian drug metabolism. Nevertheless, the latest de-
velopments in automatic programs to calculate different
14 MERCKX ET AL.
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parameters of blood vessel formation and advanced imaging
techniques, such as two-photon microscopy, make this tool
an innovative and quantifiable assay, suitable for the tissue
regeneration challenges of the 21st century.
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